ERBB2 and breast carcinoma: After confirming a gratifying synergistic effect of pyrotinib and chrysin in anti-HER2-positive breast cancer, we further investigated the underlying mechanism by which pyrotinib in combination with chrysin repressed the survival and proliferation of HER2-positive breast cancer cells.